Growth hormone releasing peptide-6 (GHRP-6) ameliorates acute lung injury and its subsequent evolvement to interstitial fibrosis.
This mouse study investigated whether Growth Hormone Releasing Peptide-6 (GHRP-6) could protect against acute lung injury (ALI) and its progression to pulmonary fibrosis. Researchers used two established animal models: intratracheal lipopolysaccharide (LPS) instillation and a combined zymosan (ZYM) plus platelet-activating factor (PAF) injection. Both acute (24-hour to 15-day) and chronic (28-day) scenarios were examined. In the acute setting, GHRP-6 treatment was associated with reduced neutrophilic alveolitis, improved lung compliance, better alveolar-capillary permeability, and lower serum interleukin-1 beta levels compared to saline controls. In the chronic setting, GHRP-6-treated animals showed better preservation of lung parenchymal architecture and notably less collagen accumulation, suggesting reduced progression to fibrosis. The authors describe this as the first assessment of GHRP-6's protective potential in lung injury models. Key limitations include exclusive use of mouse models with no human data, multiple treatment variables across scenarios, and the lack of mechanistic depth regarding GHRP-6's specific molecular targets in lung tissue. The authors conclude that findings warrant future investigation into GHRP-6's pneumoprotective effects.
Why this grade: All experiments were conducted exclusively in mouse models of lung injury with no human participants or clinical data, placing this firmly in the preclinical/animal-only evidence category.
Acute lung injury/acute respiratory distress syndrome is a complex, characterized by acute onset, alveolar damage, and progressive hypoxemia. The subsequent proliferative phase drives to pulmonary fibrosis. Lipopolysaccharide (LPS) and zymosan (ZYM) induced lung injury are commonly used biomodels that recapitulate multiple pathogenic hallmarks. We examined the ability of growth hormone releasing peptide 6 (GHRP-6) to attenuate the pulmonary damages associated with intratracheal instillation of LPS or ZYM combined injection with platelet activating factor (PAF) in mice. For the acute scenario, mice received LPS challenge and 6 h later, assigned to normal saline (Control) or to a single administration of each GHRP-6 dose and evolved for 24 h; or mice received four ZYM tracheal instillations and 6 h after, one PAF injection assigned to normal saline (Control) or to five administrations of each GHRP-6 dose and evolved for 15 days. For the chronic scenario, mice were terminated 28 days after receiving a single LPS instillation and seven subsequent daily administrations of GHRP-6; or mice were terminated 28 days after receiving five GHRP-6 therapeutic interventions after four ZYM tracheal instillations and one PAF injection. The acute scenario, GHRP-6 reduced neutrophilic alveolitis, attenuated lung compliance failure, contributed to improve alveolar-capillary permeability, and reduced interleukin-1 beta serum levels. The chronic scenario, GHRP-6 preserved lung parenchymal integrity accounted for meager collagen accumulation. This is the first assessment on the potential protective of GHRP-6 in model of lung damages. This study therefore paves the way for future research on the potential pneumoprotective effects of GHRP-6.
Educational summary of published research — not medical advice. Full text is shown only where licensing permits.